Seminars in Oncology
Volume 35 , Pages S1-S14 , April 2008

Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer: Intrinsic and Acquired

  • A. Jo Chien
    • ,
  • Mark M. Moasser

      Affiliations

    • Corresponding Author InformationAddress correspondence to Mark M. Moasser, MD, University of California, San Francisco Comprehensive Cancer Center, PO Box 0875, San Francisco, CA 94143-0875

References 

  1. Piccart M. The role of taxanes in the adjuvant treatment of early stage breast cancer. Breast Cancer Res Treat. 2003;79(suppl 1):S25–S34
  2. Sparano JA. Taxanes for breast cancer: An evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer. 2000;1:32–40
  3. Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am. 2001;15:525–545
  4. du Bois A, Neijt JP, Thigpen JT. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer–A new standard of care?. Ann Oncol. 1999;10(suppl 1):35–41
  5. Conlin AK, Seidman AD. Taxanes in breast cancer: an update. Curr Oncol Rep. 2007;9:22–30
  6. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann Rev Med. 1997;48:353–374
  7. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983
  8. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst. 2000;92:699–708
  9. Greco FA. Paclitaxel-based combination chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2001;34(suppl 4):S53–S56
  10. Greco FA, Hainsworth JD. The evolving role of paclitaxel for patients with carcinoma of unknown primary site. Semin Oncol. 1999;26(suppl 2):129–133
  11. Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol. 1982;94:688–696
  12. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol. 1981;91:479–487
  13. Nogales E, Wolf SG, Khan IA, et al. Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature. 1995;375:424–427
  14. Rao S, He L, Chakravarty S, et al. Characterization of the Taxol binding site on the microtubule (Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol). J Biol Chem. 1999;274:37990–37994
  15. Snyder JP, Nettles JH, Cornett B, et al. The binding conformation of Taxol in beta-tubulin: A model based on electron crystallographic density. Proc Natl Acad Sci U S A. 2001;98:5312–5316
  16. Nogales E. Structural insights into microtubule function. Ann Rev Biochem. 2000;69:277–302
  17. Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. Biochemistry. 1981;20:3247–3252
  18. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665–667
  19. Jordan MA, Toso RJ, Thrower D, et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A. 1993;90:9552–9556
  20. Jordan MA, Wendell K, Gardiner S, et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996;56:816–825
  21. Abal M, Souto AA, Amat-Guerri F, et al. Centrosome and spindle pole microtubules are main targets of a fluorescent taxoid inducing cell death. Cell Motil Cytoskeleton. 2001;49:1–15
  22. Milross CG, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst. 1996;88:1308–1314
  23. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996;56:1253–1255
  24. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A. 1995;92:4507–4511
  25. Blagosklonny MV, Schulte TW, Nguyen P, et al. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res. 1995;55:4623–4626
  26. Vasey PA, Jones NA, Jenkins S, et al. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol. 1996;50:1536–1540
  27. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57:4285–4300
  28. Debernardis D, Sire EG, De Fendis P, et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res. 1997;57:870–874
  29. Reinecke P, Kalinski T, Mahotka C, et al. Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status. Cancer Lett. 2005;222:165–171
  30. Blagosklonny MV, Giannakakou P, el-Deiry WS, et al. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer Res. 1997;57:130–135
  31. Bacus SS, Gudkov AV, Lowe M, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 2001;20:147–155
  32. Seidman R, Gitelman I, Sagi O, et al. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res. 2001;268:84–92
  33. Rasouli-Nia A, Liu D, Perdue S, et al. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. Clin Cancer Res. 1998;4:1111–1116
  34. McDaid HM, Lopez-Barcons L, Grossman A, et al. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 2005;65:2854–2860
  35. McDaid HM, Horwitz SB. Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol. 2001;60:290–301
  36. Yen WC, Prudente RY, Lamph WW. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res Treat. 2004;88:141–148
  37. Shi B, Yaremko B, Hajian G, et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol. 2000;46:387–393
  38. Iancu C, Mistry SJ, Arkin S, et al. Taxol and anti-stathmin therapy: A synergistic combination that targets the mitotic spindle. Cancer Res. 2000;60:3537–3541
  39. Tortora G, di Isernia G, Sandomenico C, et al. Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res. 1997;57:5107–5111
  40. Jekunen AP, Christen RD, Shalinsky DR, et al. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer. 1994;69:299–306
  41. Vigano L, Locatelli A, Grasselli G, et al. Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy. Invest New Drugs. 2001;19:179–196
  42. Ozols RF. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol. 2000;27(suppl 1):3–7
  43. Motzer RJ. Paclitaxel (Taxol) combination therapy for resistant germ cell tumors. Semin Oncol. 2000;27(suppl 1):33–35
  44. Hortobagyi GN. Paclitaxel-based combination chemotherapy for breast cancer. Oncology (Williston Park). 1997;11(suppl 2):29–37
  45. Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother. 2002;3:755–766
  46. Rowinsky EK. Paclitaxel pharmacology and other tumor types. Semin Oncol. 1997;24(suppl 19):1–12
  47. Litman T, Druley TE, Stein WD, et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci. 2001;58:931–959
  48. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11:1156–1166
  49. Mechetner E, Kyshtoobayeva A, Zonis S, et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res. 1998;4:389–398
  50. Alvarez M, Paull K, Monks A, et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest. 1995;95:2205–2214
  51. Lautier D, Canitrot Y, Deeley RG, et al. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol. 1996;52:967–977
  52. Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci. 2000;113:2011–2021
  53. Huisman MT, Chhatta AA, van Tellingen O, et al. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005;116:824–829
  54. Hopper-Borge E, Chen ZS, Shchaveleva I, et al. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): Resistance to docetaxel. Cancer Res. 2004;64:4927–4930
  55. Müller M. Human ABC transporters. http://nutrigene.4t.com/humanabc.htm(accessed December 19, 2007)
  56. Duan Z, Feller AJ, Penson RT, et al. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: Analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res. 1999;5:3445–3453
  57. Parekh H, Wiesen K, Simpkins H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol. 1997;53:461–470
  58. Liang Y, Meleady P, Cleary I, et al. Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur J Cancer. 2001;37:1041–1052
  59. Roy SN, Horwitz SB. A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res. 1985;45:3856–3863
  60. Bhalla K, Huang Y, Tang C, et al. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia. 1994;8:465–475
  61. Moran E, Cleary I, Larkin AM, et al. Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42. Eur J Cancer. 1997;33:652–660
  62. Dumontet C, Duran GE, Steger KA, et al. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res. 1996;56:1091–1097
  63. Schöndorf T, Neumann R, Benz C, et al. Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Recent Results Cancer Res. 2003;161:111–116
  64. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther. 2004;3:833–838
  65. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003;63:1515–1519
  66. Duraj J, Sedlak J, Bies J, et al. PSC 833 modulation of multidrug resistance to paclitaxel in cultured human ovarian carcinoma cells leads to apoptosis. Anticancer Res. 2002;22:3425–3428
  67. Duraj J, Takacsova X, Sedlak J, et al. PSC 833 induces apoptosis in drug-sensitive human leukemia cell line and modulates resistance to paclitaxel in its multidrug-resistant variant. Anticancer Res. 2000;20:4627–4632
  68. Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: A study in serial samples. Gynecol Oncol. 2004;93:98–106
  69. Kamazawa S, Kigawa J, Kanamori Y, et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2002;86:171–176
  70. Yeh JJ, Hsu WH, Wang JJ, et al. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration. 2003;70:32–35
  71. Beck JF, Bohnet B, Brügger D, et al. Expression analysis of protein kinase C isozymes and multidrug resistance associated genes in ovarian cancer cells. Anticancer Res. 1998;18:701–705
  72. Yang X, Uziely B, Groshen S, et al. MDR1 gene expression in primary and advanced breast cancer. Lab Invest. 1999;79:271–280
  73. Ozalp SS, Yalcin OT, Tanir M, et al. Multidrug resistance gene-1 (Pgp) expression in epithelial ovarian malignancies. Eur J Gynaecol Oncol. 2002;23:337–340
  74. Seiden MV, Swenerton KD, Matulonis U, et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002;86:302–310
  75. Toppmeyer D, Seidman AD, Pollak M, et al. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res. 2002;8:670–678
  76. Berrieman HK, Lind MJ, Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy?. Lancet Oncol. 2004;5:158–164
  77. Sullivan KF, Cleveland DW. Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. Proc Natl Acad Sci U S A. 1986;83:4327–4331
  78. Panda D, Miller HP, Banerjee A, et al. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A. 1994;91:11358–11362
  79. Lu Q, Luduena RF. In vitro analysis of microtubule assembly of isotypically pure tubulin dimers (Intrinsic differences in the assembly properties of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers in the absence of microtubule-associated proteins). J Biol Chem. 1994;269:2041–2047
  80. Banerjee A, Roach MC, Trcka P, et al. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem. 1990;265:1794–1799
  81. Derry WB, Wilson L, Khan IA, et al. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry. 1997;36:3554–3562
  82. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997;100:1282–1293
  83. Jaffrézou JP, Dumontet C, Derry WB, et al. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res. 1995;7:517–527
  84. Ranganathan S, Benetatos CA, Colarusso PJ, et al. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer. 1998;77:562–566
  85. Nicoletti MI, Valoti G, Giannakakou P, et al. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: Correlation with sensitivity to microtubule active agents. Clin Cancer Res. 2001;7:2912–2922
  86. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer. 1999;80:1020–1025
  87. Ferlini C, Raspaglio G, Mozzetti S, et al. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res. 2005;65:2397–2405
  88. Ranganathan S, Dexter DW, Benetatos CA, et al. Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochim Biophys Acta. 1998;1395:237–245
  89. Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005;11:298–305
  90. Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer. 2005;92:E25–E30
  91. Han EK, Gehrke L, Tahir SK, et al. Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines. Eur J Cancer. 2000;36:1565–1571
  92. Cassimeris L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol. 2002;14:18–24
  93. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell. 1996;84:623–631
  94. Larsson N, Segerman B, Gradin HM, et al. Mutations of oncoprotein 18/stathmin identify tubulin-directed regulatory activities distinct from tubulin association. Mol Cell Biol. 1999;19:2242–2250
  95. Iancu C, Mistry SJ, Arkin S, et al. Effects of stathmin inhibition on the mitotic spindle. J Cell Sci. 2001;114:909–916
  96. Chang W, Gruber D, Chari S, et al. Phosphorylation of MAP4 affects microtubule properties and cell cycle progression. J Cell Sci. 2001;114:2879–2887
  97. Chapin SJ, Lue CM, Yu MT, et al. Differential expression of alternatively spliced forms of MAP4: A repertoire of structurally different microtubule-binding domains. Biochemistry. 1995;34:2289–2301
  98. Poruchynsky MS, Giannakakou P, Ward Y, et al. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem Pharmacol. 2001;62:1469–1480
  99. Murphy M, Hinman A, Levine AJ. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev. 1996;10:2971–2980
  100. Zhang CC, Yang JM, White E, et al. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene. 1998;16:1617–1624
  101. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005;102:8315–8320
  102. Gonzalez-Garay ML, Chang L, Blade K, et al. A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem. 1999;274:23875–23882
  103. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997;272:17118–17125
  104. Wiesen K, Xia S, Horwitz SB. Exogenous class I beta-tubulin sensitizes taxol-resistant MDA cells. Proc Am Assoc Cancer Res. 2002;43:788;Abstr 3906
  105. Martello LA, Verdier-Pinard P, Shen HJ, et al. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res. 2003;63:1207–1213
  106. Orr GA, Verdier-Pinard P, McDaid H, et al. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22:7280–7295
  107. He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to Taxol. Drug Discov Today. 2001;6:1153–1164
  108. Kelley MJ, Li S, Harpole DH. Genetic analysis of the beta-tubulin gene, TUBB, in non–small-cell lung cancer. J Natl Cancer Inst. 2001;93:1886–1888
  109. Tsurutani J, Komiya T, Uejima H, et al. Mutational analysis of the beta-tubulin gene in lung cancer. Lung Cancer. 2002;35:11–16
  110. Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol. 1999;17:1786–1793
  111. McDaid HM, Mani S, Shen HJ, et al. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res. 2002;8:2035–2043
  112. Hasegawa S, Miyoshi Y, Egawa C, et al. Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int J Cancer. 2002;101:46–51
  113. Kohonen-Corish MR, Qin H, Daniel JJ, et al. Lack of beta-tubulin gene mutations in early stage lung cancer. Int J Cancer. 2002;101:398–399
  114. de Castro J, Belda-Iniesta C, Cejas P, et al. New insights in beta-tubulin sequence analysis in non-small cell lung cancer. Lung Cancer. 2003;41:41–48
  115. Lamendola DE, Duan Z, Penson RT, et al. Beta tubulin mutations are rare in human ovarian carcinoma. Anticancer Res. 2003;23:681–686
  116. Maeno K, Ito K, Hama Y, et al. Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer. Cancer Lett. 2003;198:89–97
  117. Mesquita B, Veiga I, Pereira D, et al. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer. 2005;5:101
  118. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: Aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005;5:773–785
  119. Castro A, Bernis C, Vigneron S, et al. The anaphase-promoting complex: A key factor in the regulation of cell cycle. Oncogene. 2005;24:314–325
  120. Sudo T, Nitta M, Saya H, et al. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 2004;64:2502–2508
  121. Lee EA, Keutmann MK, Dowling ML, et al. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther. 2004;3:661–669
  122. Burns TF, Fei P, Scata KA, et al. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol. 2003;23:5556–5571
  123. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 2003;3:51–62
  124. Dutertre S, Prigent C. Aurora-A overexpression leads to override of the microtubule-kinetochore attachment checkpoint. Mol Interv. 2003;3:127–130
  125. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55:2325–2333
  126. Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science. 2004;305:866–869
  127. Bode CJ, Gupta ML, Reiff EA, et al. Epothilone and paclitaxel: Unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry. 2002;41:3870–3874
  128. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429–1437
  129. Chou TC, Zhang XG, Balog A, et al. Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci U S A. 1998;95:9642–9647
  130. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures–A new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta. 2000;1470:M79–M91
  131. Chou TC, O'Connor OA, Tong WP, et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci U S A. 2001;98:8113–8118
  132. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 1997;8:161–170
  133. Tanabe KM, Millward M, Allen JD. Interactions of patupilone (epothilone B) with multidrug transporter proteins. Proc Am Assoc Cancer Res. 2005;46:(abstr 3430). Available at: http://www.aacrmeetingabstracts.org (accessed March 17, 2008)
  134. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J Biol Chem. 1997;272:2534–2541
  135. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A. 2000;97:2904–2909
  136. Goodin S, Kane MP, Rubin EH. Epothilones: Mechanism of action and biologic activity. J Clin Oncol. 2004;22:2015–2025
  137. Wang H, Mao Y, Zhou N, et al. Atp-bound topoisomerase ii as a target for antitumor drugs. J Biol Chem. 2001;276:15990–15995
  138. Minotti G, Licata S, Saponiero A, et al. Anthracycline metabolism and toxicity in human myocardium: Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite. Chem Res Toxicol. 2000;13:1336–1341
  139. Jacobson MD. Reactive oxygen species and programmed cell death. Trends Biochem Sci. 1996;21:83–86
  140. Muller I, Niethammer D, Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity. Int J Mol Med. 1998;1:491–494
  141. Kemp CJ, Sun S, Gurley KE. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res. 2001;61:327–332
  142. Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets. 2000;1:85–99
  143. Renes J, de Vries EG, Jansen PL, et al. The (patho)physiological functions of the MRP family. Drug Resist Updat. 2000;3:289–302
  144. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983;221:1285–1288
  145. Seelig A, Blatter XL, Wohnsland F. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison. Int J Clin Pharmacol Ther. 2000;38:111–121
  146. Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta. 1999;1461:359–376
  147. Borst P, Evers R, Kool M, et al. A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295–1302
  148. Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clin Cancer Res. 2003;9:827–836
  149. Dalton WS, Scheper RJ. Lung resistance-related protein: Determining its role in multidrug resistance. J Natl Cancer Inst. 1999;91:1604–1605
  150. Scheffer GL, Schroeijers AB, Izquierdo MA, et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol. 2000;12:550–556
  151. Kitazono M, Sumizawa T, Takebayashi Y, et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst. 1999;91:1647–1653
  152. Kitazono M, Okumura H, Ikeda R, et al. Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int J Cancer. 2001;91:126–131
  153. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95:15665–15670
  154. Bustamante J, Galleano M, Medrano EE, et al. Adriamycin effects on hydroperoxide metabolism and growth of human breast tumor cells. Breast Cancer Res Treat. 1990;17:145–153
  155. Doroshow JH. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun. 1986;135:330–335
  156. Pani G, Bedogni B, Anzevino R, et al. Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells. Cancer Res. 2000;60:4654–4660
  157. Sgambato A, Camerini A, Pani G, et al. Increased expression of cyclin E is associated with an increased resistance to doxorubicin in rat fibroblasts. Br J Cancer. 2003;88:1956–1962
  158. Harbottle A, Daly AK, Atherton K, et al. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer. 2001;92:777–783
  159. Furusawa S, Kimura E, Kisara S, et al. Mechanism of resistance to oxidative stress in doxorubicin resistant cells. Biol Pharm Bull. 2001;24:474–479
  160. Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996;2:811–814
  161. Vikhanskaya F, D'Incalci M, Broggini M. Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int J Cancer. 1995;61:397–401
  162. Hochhauser D, Valkov NI, Gump JL, et al. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines. J Cell Biochem. 1999;75:245–257
  163. Lam V, McPherson JP, Salmena L, et al. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res. 1999;23:871–880
  164. Fulda S, Sieverts H, Friesen C, et al. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997;57:3823–3829
  165. Inoue A, Narumi K, Matsubara N, et al. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett. 2000;157:105–112
  166. Dunkern TR, Wedemeyer I, Baumgartner M, et al. Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair (Amst). 2003;2:49–60
  167. Gieseler F, Bauer E, Nuessler V, et al. Molecular effects of topoisomerase II inhibitors in AML cell lines: Correlation of apoptosis with topoisomerase II activity but not with DNA damage. Leukemia. 1999;13:1859–1863
  168. Lage H, Helmbach H, Dietel M, et al. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer. 2000;82:488–491
  169. Ramachandran C, Samy TS, Huang XL, et al. Doxorubicin-induced DNA breaks, topoisomerase II activity and gene expression in human melanoma cells. Biochem Pharmacol. 1993;45:1367–1371
  170. Eijdems EW, de Haas M, Timmerman AJ, et al. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines. Br J Cancer. 1995;71:40–47
  171. Salvatore C, Camarda G, Maggi CA, et al. NF-kappaB activation contributes to anthracycline resistance pathway in human ovarian carcinoma cell line A2780. Int J Oncol. 2005;27:799–806
  172. Mechetner E, Kyshtoobayeva A, Zonis S, et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res. 1998;4:389–398
  173. Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: A study in serial samples. Gynecol Oncol. 2004;93:98–106

 Drs Chien and Moasser have no relevant financial relationships with commercial interests to disclose.

PII: S0093-7754(08)00050-X

doi: 10.1053/j.seminoncol.2008.02.010

Seminars in Oncology
Volume 35 , Pages S1-S14 , April 2008

Article Tools

* Image Usage & Resolution